The prediction was not improved by replacing these tests with CSF measurement of P-Tau, Aβ40 and Aβ42, indicating that a selection of appropriate non-invasive biomarkers may be sufficient for clinical prediction and diagnosis of AD in the future. This evidence concerns the gene MAPT and Alzheimer disease.